Editas Medicine (EDIT) Operating Leases (2019 - 2025)
Editas Medicine (EDIT) posted quarterly Operating Leases of $12.1 million for Q4 2025, down 40.77% year-over-year from $20.4 million in Q4 2024, and down 11.01% quarter-over-quarter from $13.6 million in Q3 2025.
Editas Medicine (EDIT) Operating Leases (2019 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Operating Leases for 7 consecutive years, with $12.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Leases fell 40.77% year-over-year to $12.1 million; the TTM figure through Dec 2025 stood at $12.1 million (down 40.77% YoY), while the FY2025 annual figure was $12.1 million, down 40.77% from the prior year.
- Operating Leases fell to $12.1 million in Q4 2025 per EDIT's latest filing, from $13.6 million in the prior quarter.
- Across five years, Operating Leases topped out at $32.9 million in Q4 2022 and bottomed at $9.3 million in Q3 2022.
- Historically, Operating Leases has averaged $19.5 million across 5 years, with a median of $20.4 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Leases tumbled 52.5% — and 2023, when it surged 167.13%.
- Editas Medicine's Operating Leases stood at $16.1 million in 2021, then jumped by 104.52% to $32.9 million in 2022, then fell by 25.84% to $24.4 million in 2023, then dropped by 16.38% to $20.4 million in 2024, then tumbled by 40.77% to $12.1 million in 2025.
- Business Quant data shows EDIT's Operating Leases at $12.1 million in Q4 2025, $13.6 million in Q3 2025, and $15.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 12.07 Mn |
| Sep 30, 2025 | 13.56 Mn |
| Jun 30, 2025 | 14.99 Mn |
| Mar 31, 2025 | 17.97 Mn |
| Dec 31, 2024 | 20.38 Mn |
| Sep 30, 2024 | 22.10 Mn |
| Jun 30, 2024 | 20.51 Mn |
| Mar 31, 2024 | 21.78 Mn |
| Dec 31, 2023 | 24.37 Mn |
| Sep 30, 2023 | 24.92 Mn |
| Jun 30, 2023 | 26.86 Mn |
| Mar 31, 2023 | 28.81 Mn |
| Dec 31, 2022 | 32.86 Mn |
| Sep 30, 2022 | 9.33 Mn |
| Jun 30, 2022 | 10.11 Mn |
| Mar 31, 2022 | 12.96 Mn |
| Dec 31, 2021 | 16.07 Mn |
| Sep 30, 2021 | 18.43 Mn |
| Jun 30, 2021 | 21.28 Mn |
| Mar 31, 2021 | 21.62 Mn |